• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Special Reports
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Resources
    • About MassDevice
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
    • In-Depth Coverage
    • Latest News
  • Attend DeviceTalks
    • Events
      • DeviceTalks Minnesota – May 4
      • DeviceTalks Boston – May 27–28
      • DeviceTalks West
      • DeviceTalks Tuesdays
    • DeviceTalks Podcast Network
      • DeviceTalks Weekly
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Advertise
  • Subscribe
Home » Philips gets FDA green light for scanner platform

Philips gets FDA green light for scanner platform

April 22, 2026 By Sean Whooley

Philips Rembra RT CT Scanner
The Rembra RT scanner [Image courtesy of Philips]
Philips (NYSE:PHG) announced today that it received FDA 510(k) clearance for its Rembra platform of scanning systems.

The Rembra platform includes the Rembra CT, Rembra RT and Areta RT systems. Philips unveiled Rembra CT, its next-generation radiology computed tomography (CT) imaging system, last month. It debuted Rembra RT and Areta RT in September 2025 as well, in addition to what it labels the world’s first detector-based spectral CT fully powered by AI, unveiled in December 2025.

Amsterdam-based Philips said it designed its newly cleared systems to help healthcare providers respond to the growing demand for imaging and radiation therapy planning. They help improve speed, efficiency and access to high-quality imaging.

Philips says Rembra extends the role of computed tomography (CT) across both diagnostic radiology and radiation therapy. It helps to enable more connected workflows and a coordinated approach to patient care.

Rembra CT features a largest-in-class 85-cm bore, built for the front lines of care. The company says it enables ultra-fast, high-throughput imaging, supporting up to 270 exams per day. Its use spans various settings, including emergency departments, critical care and interventional settings.

Philips said Rembra RT and Areta RT bring these advantages into radiation therapy as well. These systems support high-fidelity imaging for treatment planning. They feature a wide, 85-cm extended field of view and next-generation 4DCT imaging capabilities.

Altogether, the company says its platform offers a unified, high-performance CT ecosystem that spans the full care continuum.

Dan Xu, business leader of CT at Philips, said:

“As healthcare systems manage increasing demand and complexity, imaging plays a critical role in enabling timely and informed clinical decisions. With the Rembra platform, we are redefining what clinicians can expect from CT, combining speed, scalability, and precision to expand access to high-quality imaging while supporting confident diagnosis and highly accurate treatment planning.”

Filed Under: 510(k), Food & Drug Administration (FDA), Health Technology, Imaging, Radiosurgery/Radiation therapy, Regulatory/Compliance Tagged With: FDA, Philips, Royal Philips

More recent news

  • J&J delivers Shockwave data sustaining below-the-knee gains for two years
  • BD appoints worldwide president of Surgery business
  • Boston Scientific names COO amid cardiovascular restructuring
  • Getinge Life Science president is leaving
  • Endologix is now Rhevera Medical

About Sean Whooley

Sean Whooley is a senior editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >
MDO ad
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2026 · Arrowfly LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy